Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01383759 · OUTCOME

Percentage of Participants Experiencing Progression Free Survival at 12 Months

Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis · Source last updated 2020-04-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of patients
Interval / dispersion
95% Confidence Interval
Time frame
12 months

What was measured

of a 3-phase comprehensive treatment approach including induction with BD followed by risk adapted HDM/ASCT, followed by consolidation/maintenance therapy with BD in patients with AL amyloidosis.

Analysis population: Data were not collected for MIDD group.

Groups in this outcome

Amyloidosis

Participants with newly diagnosed AL amyloidosis

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Amyloidosis19

Reported measurements

Source class 1
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Amyloidosis84Not reported6999Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        69
        upper Limit
        99
        value
        84
denoms
  1. counts
    1. group Id
      OG000
      value
      19
    units
    Participants
description
of a 3-phase comprehensive treatment approach including induction with BD followed by risk adapted HDM/ASCT, followed by consolidation/maintenance therapy with BD in patients with AL amyloidosis.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants with newly diagnosed AL amyloidosis
    id
    OG000
    title
    Amyloidosis
param Type
NUMBER
population Description
Data were not collected for MIDD group.
reporting Status
POSTED
time Frame
12 months
title
Percentage of Participants Experiencing Progression Free Survival at 12 Months
type
PRIMARY
unit Of Measure
percentage of patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice